<DOC>
	<DOC>NCT00334178</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine</brief_title>
	<detailed_description>The purpose of this study is to evaluate the efficacy and safety of Laxymig® ER compared with placebo in prophylactic monotherapy treatment of migraine headache. Four weeks baseline, following with 12 weeks treatment phase. Subjects migraine are recorded by diary cards and re-evaluated by the investigator. Subject will have visit every 4-week (+/- 7 days).</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine with Aura</mesh_term>
	<criteria>Clinical diagnosis of migraine with or without aura (typical aura with migraine headache) Subjects who had an average of two or more migraine frequencies per month during the 3 months before screening Female subjects who are pregnant, lactating Chronic daily headache Previous treatment with three or more migraine prophylaxis medications failed Subjects with hepatic disease whose liver enzymes are over 2 times of upper limit of reference or significant dysfunction Coexisting medical, neurological, or psychiatric disorder that may hinder the study according to the investigator's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Migraine prophylaxis</keyword>
</DOC>